Biopharmaceutical companies invest large amount of resources to develop and launch new products for cardiovascular therapeutic areas. However, the complexity of a new cardiovascular product launch is compounded by the many pitfalls that are part of the market-entry landscape.
Best Practices ®, LLC undertook this research to showcase current and future risk levels for various pitfalls across critical launch fronts that can derail a new cardiovascular product. Pharmaceutical launch executives can use this study to better understand the potential pitfalls and stumbling blocks that they'll have to navigate as part of a new cardiovascular product entering the market.
Study Overview–- This study explores the executive insights, best practices and lessons learned to avoid common pitfalls while launching a new cardiovascular product into market.
About the Benchmark Class - Forty four executives from 38 leading companies including Abbott, Amgen, Baxter, Bayer, Eisai, GlaxoSmithKline, Merck, Novartis, and Roche participated in this study. Majority of the respondents were at vice president or director level.
Section 1: Study Background -- Reviews the study background, the research approach, methodology, participant demographics, the benchmark class and key findings.
Section 2: Topical chapters -- Outlines valuable insights and findings from the study that includes pitfalls & stumbling blocks, lessons learned and best practices and future changes. Pitfalls chapter reviews current and future risk levels for these cardiovascular launch factors: product shaping, market shaping, physician, patient, payer, internal and regulatory.
Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...Best Practices
*Oncology, Metabolic, and Cardiovascular segmentations are available. The summaries can be found under the "New Product Planning and Launch" portion of our SlideShare channel.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
International Pharmaceutical Industry: Feasibility Is Not (Anymore) A Plain S...KCR
Investigational Sites
The sole term ‘feasibility’ has multiple definitions in a clinical environment, leading to certain bias with all stakeholders involved, including pharma companies (sponsors) and all types of contract research organizations (CROs). The most common perception is related to a never-ending argument between pharma outsourcing departments and CRO commercial groups, with sponsors expecting CROs to run a (non-defined) feasibility study prior to proposal submission and CROs undertaking a series of schematic actions to create an impression of fulfilled expectation.
A workshop presentation for Medical Affairs Strategic Summit West held in San Diego on September 23, 2019. The workshop covered the following learning objectives:
* Understand the factors involved in selecting and prioritizing indications
* Understand the importance of strategic market segmentation
* Understand how Medical Affairs can be involved in the process of new product planning
Success Factors and Failure Points in Biopharmaceutical Product Launches: An ...Best Practices
*Oncology, Metabolic, and Cardiovascular segmentations are available. The summaries can be found under the "New Product Planning and Launch" portion of our SlideShare channel.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
International Pharmaceutical Industry: Feasibility Is Not (Anymore) A Plain S...KCR
Investigational Sites
The sole term ‘feasibility’ has multiple definitions in a clinical environment, leading to certain bias with all stakeholders involved, including pharma companies (sponsors) and all types of contract research organizations (CROs). The most common perception is related to a never-ending argument between pharma outsourcing departments and CRO commercial groups, with sponsors expecting CROs to run a (non-defined) feasibility study prior to proposal submission and CROs undertaking a series of schematic actions to create an impression of fulfilled expectation.
A workshop presentation for Medical Affairs Strategic Summit West held in San Diego on September 23, 2019. The workshop covered the following learning objectives:
* Understand the factors involved in selecting and prioritizing indications
* Understand the importance of strategic market segmentation
* Understand how Medical Affairs can be involved in the process of new product planning
Early asset development and commercialization: Partnering for successCello Health
To be successful in developing an asset you have to identify the need and define the commercial value early on in the development process, as well as revisiting and refining the value as you progress through the phases of development. This means understanding what else is coming onto the market from a competitive perspective and the clinical relevance from a patient perspective. Being mindful about value throughout development is also important because, at each phase more investment will be needed, especially in smaller companies. Often times the need for investment results in a licensing agreement or a partnership.
This is a follow up webinar to "The value of early asset development and commercialization." The slides take a deep dive into how to find the right partner for developing and commercializing your asset.
This presentation explores some of the underlying issues responsible for declining pharma R&D productivity, and provides a new, fully integrated approach to reverse this trend by navigating R&D projects and portfolios through the risk-return landscape in real time.
A case study demonstrates how this system can be used in practice to improve the risk-return profile of a Phase 2 development project according to risk appetite.
This presentation focuses on R&D in the pharmaceutical industry, however the approach can be used to manage and optimize the risk-return profile of any business asset at any stage of its lifecycle, at any level, in any industry.
Effective Pharmaceutical Life Cycle Management Planning: Optimizing Product V...Nick DeSanctis
Developing an effective drug life cycle management plan is critical for maximizing the value of a pharma product over the course of its commercial lifespan. Drawing from our deep expertise of pharmaceutical product lifecycle management, RxC International, a life sciences management consulting firm, has identified key success factors and industry best practices as well as common pitfalls to avoid when developing and implementing LCM plans.
Aagami Market Intelligence PresentationAagami, Inc.
Aagami, Inc., is a life sciences consulting firm offering,
· Market Intelligence
· Strategic Consulting
· Technology Licensing
For Global companies in
· Pharma
· Biotech
· Consumer Healthcare
· Technology Licensing Office of Universities
· Medical Devices & Technology
· CROs, CDMOs
In Brief, Aagami Brings:
· Deep Experience of overcoming business and socio-cultural differences of various countries
· Supplementing your bandwidth to save time, effort & cost
· Global Deal experience, honed for decades
· Partners having combined experience of 250+ years
· Extensive ‘C’ level network nurtured for over 15 years
75+ Bio Pharma clients globally across 125+ assignments have put their trust in Aagami since 2003.
Lifecycle Management in the Pharmaceutical IndustryAnthony Russell
Presented to students in the Drug Development and Product Management program at UC San Diego. Covers the rationale for lifecycle management is important. Includes case studies of successful implementation of lifecycle management. Presentation date: 2/5/2019.
How to Work Effectively with Research Teams in New Product PlanningAnthony Russell
Presented at the 3rd New Product Planning Summit. The presentation was designed to help professionals in New Product Planning to present a case for why commercial strategy input is needed early in the process of developing new therapeutics. The presentation also includes suggested approaches and tools to help with effective engagement with Research teams.
Shift Health co-hosted a Product Development Boot Camp with the Global HIV Vaccine Enterprise. The Boot Camp afforded workshop participants an opportunity to discuss best practices, to learn from the experience of other experts and to create an enduring resource and toolkit that will serve the HIV vaccine field and beyond.
Product development refers to the multifaceted, long-term, highly regulated process that brings promising new drugs, vaccines and medical devices to the populations who most need them. In fields such as HIV vaccine development, where the absence of commercial incentives can make it difficult for companies to lead this process on their own, inventors need to work in partnership with diverse stakeholders and funders to maximize the social and economic impact of their research.
Anne Mullin, PhD, Engagement Leader, Director, Team Performance and Development at Shift Health, outlined the elements of planning for trial success:
Build contingency plans around potential scenarios
Define proactive and reactive responses in a prescriptive and unambiguous manner
Ensure that contingency plans set the stage for future product access.
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...Best Practices
Competitive Assessments and Clinical Landscape Assessments are crucial to the success of new products in the pharmaceutical industry. In order to inform busy executives quickly and effectively, market intelligence and analytics leaders must develop briefing templates that are clear, concise, and impactful.
This study identifies winning strategies for effectively informing senior leaders through Competitive Landscape Summaries and Clinical Development Profile Maps. The research will help executives to understand what the important elements to include are, and what are the best formats for two critical healthcare briefing templates: : 1) the Competitive Landscape Summary Map and 2) the Development Landscape Profile Map (often described as the Data Disclosure or Clinical Trials Progress Summary).
Read more at: http://www.best-in-class.com/bestp/domrep.nsf/products/developing-high-impact-communication-forms-to-brief-senior-leaders-optimizing-competitive-assessment-data-disclosure-summaries?OpenDocument
Building a Business Case for New Product Planning in a Small Company EnvironmentAnthony Russell
Presented at the 2nd New Product Planning Summit by ExL Events in Boston (Dec 8, 2017). An overview of why commercial strategy is needed early in product development. As pressures continue to mount in drug development (crowded markets, payer and access issues, etc.), it is becoming critical to focus on the early stages of drug development. Working early with research and development teams to evaluate the commercial viability of programs will benefit companies of all sizes to maximize their portfolio of therapeutic candidates.
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
Early asset development and commercialization: Partnering for successCello Health
To be successful in developing an asset you have to identify the need and define the commercial value early on in the development process, as well as revisiting and refining the value as you progress through the phases of development. This means understanding what else is coming onto the market from a competitive perspective and the clinical relevance from a patient perspective. Being mindful about value throughout development is also important because, at each phase more investment will be needed, especially in smaller companies. Often times the need for investment results in a licensing agreement or a partnership.
This is a follow up webinar to "The value of early asset development and commercialization." The slides take a deep dive into how to find the right partner for developing and commercializing your asset.
This presentation explores some of the underlying issues responsible for declining pharma R&D productivity, and provides a new, fully integrated approach to reverse this trend by navigating R&D projects and portfolios through the risk-return landscape in real time.
A case study demonstrates how this system can be used in practice to improve the risk-return profile of a Phase 2 development project according to risk appetite.
This presentation focuses on R&D in the pharmaceutical industry, however the approach can be used to manage and optimize the risk-return profile of any business asset at any stage of its lifecycle, at any level, in any industry.
Effective Pharmaceutical Life Cycle Management Planning: Optimizing Product V...Nick DeSanctis
Developing an effective drug life cycle management plan is critical for maximizing the value of a pharma product over the course of its commercial lifespan. Drawing from our deep expertise of pharmaceutical product lifecycle management, RxC International, a life sciences management consulting firm, has identified key success factors and industry best practices as well as common pitfalls to avoid when developing and implementing LCM plans.
Aagami Market Intelligence PresentationAagami, Inc.
Aagami, Inc., is a life sciences consulting firm offering,
· Market Intelligence
· Strategic Consulting
· Technology Licensing
For Global companies in
· Pharma
· Biotech
· Consumer Healthcare
· Technology Licensing Office of Universities
· Medical Devices & Technology
· CROs, CDMOs
In Brief, Aagami Brings:
· Deep Experience of overcoming business and socio-cultural differences of various countries
· Supplementing your bandwidth to save time, effort & cost
· Global Deal experience, honed for decades
· Partners having combined experience of 250+ years
· Extensive ‘C’ level network nurtured for over 15 years
75+ Bio Pharma clients globally across 125+ assignments have put their trust in Aagami since 2003.
Lifecycle Management in the Pharmaceutical IndustryAnthony Russell
Presented to students in the Drug Development and Product Management program at UC San Diego. Covers the rationale for lifecycle management is important. Includes case studies of successful implementation of lifecycle management. Presentation date: 2/5/2019.
How to Work Effectively with Research Teams in New Product PlanningAnthony Russell
Presented at the 3rd New Product Planning Summit. The presentation was designed to help professionals in New Product Planning to present a case for why commercial strategy input is needed early in the process of developing new therapeutics. The presentation also includes suggested approaches and tools to help with effective engagement with Research teams.
Shift Health co-hosted a Product Development Boot Camp with the Global HIV Vaccine Enterprise. The Boot Camp afforded workshop participants an opportunity to discuss best practices, to learn from the experience of other experts and to create an enduring resource and toolkit that will serve the HIV vaccine field and beyond.
Product development refers to the multifaceted, long-term, highly regulated process that brings promising new drugs, vaccines and medical devices to the populations who most need them. In fields such as HIV vaccine development, where the absence of commercial incentives can make it difficult for companies to lead this process on their own, inventors need to work in partnership with diverse stakeholders and funders to maximize the social and economic impact of their research.
Anne Mullin, PhD, Engagement Leader, Director, Team Performance and Development at Shift Health, outlined the elements of planning for trial success:
Build contingency plans around potential scenarios
Define proactive and reactive responses in a prescriptive and unambiguous manner
Ensure that contingency plans set the stage for future product access.
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...Best Practices
Competitive Assessments and Clinical Landscape Assessments are crucial to the success of new products in the pharmaceutical industry. In order to inform busy executives quickly and effectively, market intelligence and analytics leaders must develop briefing templates that are clear, concise, and impactful.
This study identifies winning strategies for effectively informing senior leaders through Competitive Landscape Summaries and Clinical Development Profile Maps. The research will help executives to understand what the important elements to include are, and what are the best formats for two critical healthcare briefing templates: : 1) the Competitive Landscape Summary Map and 2) the Development Landscape Profile Map (often described as the Data Disclosure or Clinical Trials Progress Summary).
Read more at: http://www.best-in-class.com/bestp/domrep.nsf/products/developing-high-impact-communication-forms-to-brief-senior-leaders-optimizing-competitive-assessment-data-disclosure-summaries?OpenDocument
Building a Business Case for New Product Planning in a Small Company EnvironmentAnthony Russell
Presented at the 2nd New Product Planning Summit by ExL Events in Boston (Dec 8, 2017). An overview of why commercial strategy is needed early in product development. As pressures continue to mount in drug development (crowded markets, payer and access issues, etc.), it is becoming critical to focus on the early stages of drug development. Working early with research and development teams to evaluate the commercial viability of programs will benefit companies of all sizes to maximize their portfolio of therapeutic candidates.
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
Success Factors and Failure Points in Metabolic Product Launches Report SummaryBest Practices
Biopharmaceutical companies invest large amount of resources to develop and launch new products for metabolic therapeutic areas. However, the complexity of a new metabolic product launch is compounded by the many pitfalls that are part of the market-entry landscape.
Best Practices
®, LLC undertook this research to showcase current and future risk levels for various pitfalls across critical launch fronts that can derail a new metabolic product. Pharmaceutical launch executives can use this study to better understand the potential pitfalls and stumbling blocks that they'll have to navigate as part of a new metabolic product entering the market.
Study Overview–-
This study explores the executive insights, best practices and lessons learned to avoid common pitfalls while launching a new metabolic product into market.
About the Benchmark Class -
Forty four executives from 38 leading companies including Abbott, Amgen, Baxter, Bayer, Eisai, GlaxoSmithKline, Merck, Novartis, and Roche participated in this study. Majority of the respondents were at vice president or director level.
Section 1: Study Background --
Reviews the study background, the research approach, methodology, participant demographics, the benchmark class and key findings.
Section 2: Topical chapters --
Outlines valuable insights and findings from the study that includes pitfalls & stumbling blocks, lessons learned and best practices and future changes. Pitfalls chapter reviews current and future risk levels for these metabolic launch factors: product shaping, market shaping, physician, patient, payer, internal and regulatory.
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryBest Practices
The Update to the wildly popular Medical Affairs Resources, Structures, and Trends research from 2009 is ready! Contains linear data and new segmentation for emerging markets.
Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.
This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...Best Practices
Medical education programs play an important role in informing health care professionals about the safe and effective use of medical devices.
To probe emerging medical education trends in the device sector, Best Practices, LLC undertook benchmarking research. In particular, this study provides benchmarks on the proper size, structure, funding channels, staffing and investment for medical education groups.
Download Full Report: http://bit.ly/2bY2NZ8
The importance of getting a Biotechnology launch right the first time and the difficulty of recovering from a slow sales trajectory suggest that there is a need to evolve the go-to-market approach to ensure launch success. Successfully bringing a product to market has been increasingly difficult as the U.S. Healthcare Market has evolved since implementation of the Affordable Care Act. Pricing has become more controlled - and value based - as healthcare costs have increased to an unsustainable level. Customers realize there is little product differentiation and the traditional Field Sales representative based go-to-market models are struggling to effectively communicate the value proposition to more demanding and informed customers and stakeholders. The results of our pre-launch survey are provided here along with recommendations for what Biotechnology companies can do to improve launch readiness.
New Product Planning in the Pharmaceutical IndustryAnthony Russell
Lecture presented in the Competitive Intelligence and Pricing course as part of the University of Southern California Master of Science in Healthcare Decision Analysis program. Presented on June 14, 2020 at USC via Zoom. The lectures gives an overview of what new product planning is in the pharmaceutical industry, what tools are used during new product evaluations, and the key elements of a new product business case. The lecture includes a couple of case studies to be worked on by the class.
Chris Cleary, Vice President of Corporate Development, Medtronic presented at MEDTECH 2014 on Fulfilling the Mission: Medtronic Embraces Change to Respond to an Evolving Healthcare Landscape.
Are You Prepared? The Next Generation of Orthopaedic Service LinesWellbe
Is your orthopedic service line keeping up with the changes in healthcare? How does orthopedics fit with the shift to greater accountability for quality and cost? How should you be adapting the service line to market changes? Find out about the next generation of service lines and some key strategies for succeeding under more accountable care, including organizational models and skill sets.
About the Speaker:
Ms. Lohmar is a founding Principal with New Heights Group. With over 25 years in the industry, Ms. Lohmar brings to client engagements specialized expertise in strategic planning, service line planning and development, integration/consolidation strategies and physician strategies, as well as facilitating organizational retreats and planning sessions. She is a frequent speaker on organizational service line development, and business planning for key service lines as orthopedics and neurosciences.
Rising Importance of Health Economics & Outcomes ResearchCitiusTech
Health Economics & Outcomes Research (HE&OR) guides stakeholders to make informed decisions regarding patient access to drugs and services. This document highlights specific use cases for healthcare information technology that add value to HE&OR.
Four Keys to Increase Healthcare Market ShareHealth Catalyst
With leadership alignment, easy access to data, and a roadmap to reach their objectives, health systems can drastically increase revenue and grow market share by applying four principles:
Key 1. Alignment.
Key 2. Vehicles.
Key 3: Five tools: access to data, data acumen; finance, vision to execution, and prioritizing outcomes.
Key 4: Education.
Access to the right data can drive changes that generate $48M in revenue, surpassing the year three market share goals in year two.
Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...Best Practices
It has become quite crucial to identify the drivers of digital marketing performance excellence in the health care industry which will enable companies to gain valuable customer insights, build effective relationships, leverage online media, and maximize revenue.
Best Practices, LLC undertook this benchmarking research to provide critical insights into how savvy bio-pharma digital marketers are enhancing the medical and commercial potential of new products, improving alignment with brand teams, acquiring and training new digital marketers, managing service delivery for key programs and optimizing insource vs. outsource mix.
Download Full Report: http://bit.ly/2gnXrIu
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Best Practices
The new product planning function within bio-pharmaceutical companies is tasked with the challenging role of delivering potential new products in shorter time frames and minimum development costs.
This Best Practices, LLC benchmarking report examines the role and impact of new product planning function on product commercialization. In particular, it examines the impact of structure, resources and activities of new product planning groups on product commercialization.
Download Full Report: http://bit.ly/2e8ErMD
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest Practices
Medical information groups within bio-pharmaceutical companies play a vital role in the management of publications and product inquiries during the commercialization of drugs.
However, recent regulatory changes in the industry have made it imperative for the Medical Affairs function to align its medical information activities with compliance requirements.
This Best Practices, LLC report establishes benchmarks on the critical requirements to create strong medical information groups. In particular, this report identifies best practices in internal collaboration, alignment of information activities with compliance requirements and the structure, leadership and resource levels required to develop best-in-class medical information groups.
Download Full Report: http://bit.ly/2ewac07
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices
The current structure of medical education emphasizes pedagogy related to the physician-patient relationship, and thus advocacy opportunities at this level. Patient and professional Advocacy Groups are important to the process of educating the marketplace on new therapies. Strong relationships with advocacy groups are important for educating the public on socially-sensitive conditions and treatment options.
Best Practices, LLC's study identifies effective practices in patient advocacy group collaboration and relationship management. This study also examines ideal structures and skill sets for pharma groups that deal with advocacy groups and emerging trends and challenges in patient advocacy.
Download Full Report: http://bit.ly/2evZ0AE
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...Best Practices
The Medical Affairs function plays an important role in health outcomes (HO) information exchange between bio-pharmaceutical organizations and key external stakeholders.
Development of robust health outcomes capabilities within Medical Affairs function requires an increase in the function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data as per stakeholders’ needs, and building real world data capabilities to generate and utilize health outcomes information.
This benchmarking research from Best Practices, LLC is designed to assist companies focused on oncology therapies find better ways to develop effective health outcomes groups. It provides current data and best practices from Medical Affairs leaders with an oncology focus at leading bio-pharmaceutical companies.
Download Full Report: http://bit.ly/2e3sl9Q
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...Best Practices
Bio-pharmaceutical organizations have long relied on medical education programs to provide latest medical knowledge to physicians and other health care professionals. However, recent compliance rules and regulations have tempered the sponsorship of some medical education programs by bio-pharmaceutical companies, as well as some third-party providers of such services.
Best Practices, LLC, undertook benchmarking research to probe emerging medical education trends at top bio-pharmaceutical companies. In particular, this research provides benchmarks on the proper size, structure, activities performed, staffing, and investment for the Medical Education function.
Download Full Report: http://bit.ly/2cf5PYb
Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. Therefore, it is absolutely critical for bio-pharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.
According to recent research by Best Practices, LLC, nearly three-quarters of the benchmarked study participants use review cycle time as a metric for determining if the market research approval process is functioning at an acceptable level. One tip that participants gave on how to control processes and to ensure high performance is to create checklists. Begin with checklists in pinch points that are most problematic, and then extend to entire process and operations. This report will help leaders to gain critical insights they need to compete successfully in a fast-changing market.
Download Full Report: http://bit.ly/2bfAhOc
Benchmarking Professional Medical Education Excellence StructuresBest Practices
Continuing Medical Education (CME) programs serve to maintain, develop or enhance the skills, knowledge and professional performance & relationships that a physician uses to provide services to patients, public and the profession. However, recent compliance and transparency rules have tempered the sponsorship of some medical education programs by bio-pharmaceutical companies as well as some third-party providers of such services. Critics such as Morris and Taitsman also prefer that the medical profession eliminate commercial support for CME.
Best Practices, LLC conducted this study to inform those who lead medical education programs at large bio-pharmaceutical companies about the proper size, resourcing and structure for the medical education function. The study looks into emerging Medical Education trends at medical device and pharmaceutical organizations regarding funding and program types.
Download Full Report: http://bit.ly/2bAUm6U
Given the stringent regulatory requirements in the health care industry, it is important for bio-pharmal companies to develop innovative Risk Evaluation and Mitigation Strategies (REMS) plans during the commercialization of certain products to ensure an acceptable risk-to-benefit ratio.
This benchmark study published by Best Practices, LLC examines how companies develop and execute successful Risk Evaluation and Mitigation Strategies (REMS) plans for newly-approved drugs in the U.S. market. This study can help bio-pharma companies in creating successful REMS programs.
Download Full Report: http://bit.ly/2aOt5Id
Budget Allocation for a Successful Bio-Pharma Product LaunchBest Practices
Bio-Pharma companies can no longer afford to rely solely on past experiences when budgeting for a new product launch in today's fast-changing, highly competitive market. This comprehensive benchmark study by Best Practices, LLC investigates current costs as well as budget and staffing allocations required for a successful drug launch.
This study can help bio-pharma leaders to develop competitive launch and pre-launch activity budgets to ensure successful U.S. market entry for new products.
Download Full Report: http://bit.ly/2aMYron
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...Best Practices
Optimizing the resource and staffing levels at medical device companies enables Regulatory Affairs leaders to prioritize roles and responsibilities, thereby driving organizational growth.
Research & Consulting leader, Best Practices, LLC engaged Regulatory Affairs leaders at 32 leading medical device companies through a benchmarking survey to capture insights regarding current and future trends shaping the Regulatory Affairs function. This study delivers benchmarks around the critical drivers of regulatory performance excellence at medical device companies.
Download Full Report: http://bit.ly/2asHvQh
Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...Best Practices
Bio-pharmaceutical companies use disease state awareness campaigns to disseminate unbranded information to external stakeholders such as physicians, patients and payers.
Best Practices, LLC undertook research to deliver benchmarks around the structure, timing, investment and activities for disease awareness programs.
Download Full Report: http://bit.ly/2a7CnUS
Library Services Benchmarks - Using Corporate Library Services in PharmaBest Practices
Libraries are custodians of invaluable information. The study - Library Services Benchmarks 2016: Corporate Library Services in the Pharmaceutical Industry published by Best Practices, LLC examines the trends and staffing benchmarks such as library staff per potential and actual users across companies providing access to library services across the bio-pharmaceutical space.
This study looks into staff with formal education level and the number of staff inside and outside the library who provide library services. This study can be used by bio-pharmaceutical companies to improve upon existing library services and staffing.
Download Full Report: http://bit.ly/29QZcbM
Effective Launch Training Practices for District Sales Managers: Optimize Per...Best Practices
Rising competition and access restrictions in the bio-pharmaceutical industry have made it critical for companies to prepare and measure the performance of their District Sales Managers (DMs) who oversee launch-related activities in the field.
Best Practices, LLC engaged 20 sales leaders from bio-pharmaceutical companies to establish benchmarks around the training and accountability of District Sales Managers at launch. Insights from this study will serve as a reference point for companies to evaluate their launch training programs for the sales force against industry benchmarks.
Download Full Report: http://bit.ly/29Gq68L
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...Best Practices
In order to develop an effective global branding program for new bio-pharmaceutical products, it is important to ensure brand consistency across all functions and geographies.
Best Practices, LLC undertook research to gather benchmarks on key aspects of the global branding process, including activities, timing, positioning, key message development, regional alignment, agency utilization & cost and the tradename process.
Download Full Report: http://bit.ly/2a1XqUV
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...Best Practices
Biopharmaceutical and medical device companies rely on advisory board for strategic inputs and guidance on various business aspects. However, successful advisory board management requires optimum investment in resources and operations. It is also important that the biopharmaceutical and medical device executives ensure quality of meetings and dialogue with advisory boards is excellent for maximum ROI.
This research from Best Practices, LLC showcase the best practices in advisory board management at mid-sized biopharmaceutical and medical device companies. It also highlights the top challenges, winning strategies and best practices for conducting advisory boards.
This presentation gives an insight into the membership benefits of Best Practices, LLC’s Medical Affairs Consortium. It also highlights some of the key benchmarks and best practices that emerged from Medical Affairs Consortium.
The Medical Affairs Consortium at Best Practices, LLC provides a dedicated platform to Medical Affairs Leaders to discuss top challenges, develop action oriented solutions, share best practices & lessons learned and explore current and future trends with regards to the Medical Affairs function and its interactions with other critical functions.
Topics for the Medical Affairs Consortium are usually determined by member requests. The Medical Affairs Consortium addresses three key areas:
• Building Strong Medical Affairs Capabilities
• Medical Affairs Launch Support Excellence
• Medical Affairs’ Critical Role in Health Economics & Outcomes Research
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...Best Practices
Pharmaceutical advisory boards provide strategic inputs and guidance to organizations on various business aspects. However, successful advisory board management requires optimum investment in resources and operations. To maximize the return on investment it is important for pharmaceutical and medical device professionals to ensure that the quality of meetings and dialogue with advisory boards is excellent.
This research from Best Practices, LLC is designed for pharmaceutical and biotech executives seeking ways to best utilize the knowledge of advisory boards. Research findings provide benchmarks on the appropriate structure for various types of advisory boards, selection of advisory board participants, advisory board operational and resource benchmarks.
Optimizing the Managed Markets Function: Roles, Structures, Resources and Act...Best Practices
Managed Market’s role within the pharmaceutical industry has increased as the influence of payers is simultaneously increasing. Organizations are now being forced to reassess managed markets resources and market markets structures to optimize these groups and to encourage overall organizational success.
Best Practices, LLC designed this benchmarking study to assess managed markets role within small and mid-cap pharmaceutical companies. The overall goal of this project was to illustrate how to have the most impact within the organization while continuing to operate on lean resource levels.
Read more at: http://www.best-in-class.com/bestp/domrep.nsf/products/optimizing-managed-markets-function-roles-structures-resources-activities?OpenDocument
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.